
Roman Prymula

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7931408/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Five Antigen Tests for SARS-CoV-2: Virus Viability Matters. Viruses, 2021, 13, 684.	1.5	29
2	Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries. Vaccine, 2021, 39, 2643-2651.	1.7	7
3	Covid-19 antigen testing: better than we know? A test accuracy study. Infectious Diseases, 2021, 53, 661-668.	1.4	14
4	Correlation of protection against varicella in a randomized Phase III varicella-containing vaccine efficacy trial in healthy infants. Vaccine, 2021, 39, 3445-3454.	1.7	7
5	Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons. Pediatric Infectious Disease Journal, 2020, 39, e1-e10.	1.1	23
6	Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement. Frontiers in Immunology, 2020, 11, 1282.	2.2	68
7	Complex Reporting of the COVID-19 Epidemic in the Czech Republic: Use of an Interactive Web-Based App in Practice. Journal of Medical Internet Research, 2020, 22, e19367.	2.1	53
8	Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study. Vaccine, 2019, 37, 176-186.	1.7	13
9	Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: 10-year follow-up of a phase 3 multicentre, observer-blind, randomised, controlled trial. Lancet Infectious Diseases, The, 2019, 19, 287-297.	4.6	33
10	Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-NaÃ ⁻ ve Children. Pediatric Infectious Disease Journal, 2019, 38, 203-210.	1.1	2
11	Vaccination in newly arrived immigrants to the European Union. Vaccine, 2018, 36, 5385-5390.	1.7	7
12	Influenza vaccination in the elderly. Human Vaccines and Immunotherapeutics, 2018, 14, 540-549.	1.4	110
13	Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial. Vaccine, 2017, 35, 395-402.	1.7	19
14	Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants. Vaccine, 2017, 35, 4603-4611.	1.7	26
15	Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia. Vaccine, 2017, 35, 5186-5193.	1.7	16
16	Comparative Epidemiologic Characteristics of Pertussis in 10 Central and Eastern European Countries, 2000-2013. PLoS ONE, 2016, 11, e0155949.	1.1	45
17	Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). Human Vaccines and Immunotherapeutics, 2016. 12. 1-18.	1.4	49
18	Varicella vaccine without human serum albumin versus licensed varicella vaccine in children during the second year of life: a randomized, double-blind, non-inferiority trial. BMC Pediatrics, 2016, 16, 7.	0.7	9

Roman Prymula

#	Article	IF	CITATIONS
19	How can we improve compliance with vaccination in Europe?. Future Microbiology, 2015, 10, 1397-1400.	1.0	1
20	Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children. Vaccine, 2015, 33, 3850-3858.	1.7	19
21	A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I). Human Vaccines and Immunotherapeutics, 2014, 10, 1993-2004.	1.4	81
22	A phase II randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II). Human Vaccines and Immunotherapeutics, 2014, 10, 2005-2014.	1.4	37
23	A repeated syphilis infection imported from Thailand in an HIV positive couple of men-who-have-sex-with-men in Czech Republic. Travel Medicine and Infectious Disease, 2014, 12, 84-87.	1.5	5
24	Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: A phase II randomized clinical trial. Vaccine, 2014, 32, 3025-3034.	1.7	52
25	Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet, The, 2014, 383, 1313-1324.	6.3	83
26	Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic paracetamol. Vaccine, 2013, 31, 2080-2088.	1.7	37
27	Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. Lancet, The, 2013, 381, 825-835.	6.3	247
28	Controversies in Vaccination. European Review, 2013, 21, S56-S61.	0.4	3
29	Regional Advisory Board Position Statement on Optimal Pneumococcal Vaccination in Adults. Update to 2011 Consensus on Adult Pneumococcal Disease: Update on Optimal Pneumococcal Vaccination in Adults. Central European Journal of Public Health, 2013, 21, 233-236.	0.4	1
30	Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules. JAMA - Journal of the American Medical Association, 2012, 307, 573-82.	3.8	247
31	Acceptance and Opinions of Intanza/IDflu Intradermal Influenza Vaccine in the Czech Republic and Turkey. Advances in Therapy, 2012, 29, 41-52.	1.3	22
32	Impact of the 10-valent pneumococcal non-typeable Haemophilus influenzae Protein D conjugate vaccine (PHiD-CV) on bacterial nasopharyngeal carriage. Vaccine, 2011, 29, 1959-1967.	1.7	63
33	10-valent pneumococcal nontypeable <i>Haemophilus influenzae</i> PD conjugate vaccine: Synflorixâ,,¢. Expert Review of Vaccines, 2009, 8, 1479-1500.	2.0	130
34	Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age. Vaccine, 2009, 28, 71-78.	1.7	81
35	Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet, The, 2009, 374, 1339-1350.	6.3	335
36	Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio virus, Haemophilus influenzae type b and control hepatitis A vaccines. Vaccine, 2008, 26, 4563-4570.	1.7	20

#	Article	IF	CITATIONS
37	Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet, The, 2006, 367, 740-748.	6.3	594